{
    "clinical_study": {
        "@rank": "1308", 
        "brief_summary": {
            "textblock": "The purpose of this protocol is:\n\n        1. To quantify the prevalence of adherence to topical mesalamine in patients with UC\n\n        2. To describe the determinants of medication adherence in patients with UC prescribed\n           topical mesalamine"
        }, 
        "brief_title": "Qualitative Study of Topical Mesalamine Adherence in Patients With Ulcerative Colitis(UC)", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Ulcerative Colitis", 
        "condition_browse": {
            "mesh_term": [
                "Colitis", 
                "Colitis, Ulcerative", 
                "Ulcer"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patient adherence with topical mesalamine is low. Behavioral and psycho-social barriers to\n      topical mesalamine adherence exist in patients with UC. These factors can be identified\n      using qualitative testing in order to develop and design appropriate behavioral\n      interventions to reduce non-adherence.\n\n      The investigators will undertake an observational study of medication persistence in 100\n      patients in the BIDMC clinic, \"Persistence Cohort\". Persistence will be measured using\n      12-month pharmacy refill data. The investigators will also employ a qualitative research\n      design with discrete choice modeling in two phases:  Phase I - Initial Interviews with 10\n      patients and Phase II - Focus Groups (2) with 5 patients each."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  must have ulcerative colitis diagnosed by a doctor at least 1 month prior to study\n             participation\n\n          -  must be prescribed topical mesalamine (e.g. Rowasa enemas or Canasa suppositories) by\n             a doctor\n\n          -  must be receiving care at Beth Israel Deaconess Medical Center\n\n        Exclusion Criteria:\n\n          -  no diagnosis of ulcerative colitis\n\n          -  no prescription for topical mesalamine\n\n          -  not receiving care at Beth Israel Deaconess Medical Center"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "The population of this study will be adults with diagnosed Ulcerative Colitis who have\n        been prescribed topical mesalamine (Rowasa/Canasa) for treatment of their ulcerative\n        colitis."
            }
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 23, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01678300", 
            "org_study_id": "2012-P-000100"
        }, 
        "intervention_browse": {
            "mesh_term": "Mesalamine"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Ulcerative Colitis", 
        "lastchanged_date": "August 16, 2013", 
        "location": {
            "contact": {
                "last_name": "Alan C Moss, MD", 
                "phone": "617-667-3197"
            }, 
            "contact_backup": {
                "last_name": "Anne E Gifford, MPH", 
                "phone": "617-667-0558"
            }, 
            "facility": {
                "address": {
                    "city": "Boston", 
                    "country": "United States", 
                    "state": "Massachusetts", 
                    "zip": "02215"
                }, 
                "name": "Beth Israel Deaconess Medical Center"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "Qualitative Study of Topical Mesalamine Adherence in Patients With Ulcerative Colitis(UC)", 
        "overall_contact": {
            "last_name": "Alan C Moss, MD", 
            "phone": "617-667-3197"
        }, 
        "overall_contact_backup": {
            "last_name": "Anne E Gifford, MPH", 
            "phone": "617-667-0558"
        }, 
        "overall_official": {
            "affiliation": "Beth Israel Deaconess Medical Center", 
            "last_name": "Alan C Moss, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Prevalence of \"non-persistence\" amongst patients prescribed topical mesalamine for UC", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01678300"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Beth Israel Deaconess Medical Center", 
            "investigator_full_name": "Alan C. Moss", 
            "investigator_title": "Director of Translational Research, Inflammatory Bowel Disease Center", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Clinical outcome (remission / relapse) based on Simple Colitis Activity Index Score", 
                "measure": "Clinical outcome (remission / relapse) at 12 months grouped by persistence status", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Prevalence of self-reported \"low adherence\" amongst patients prescribed topical mesalamine\nDemographic and disease phenotype variables associated with \"non persistence\" or \"low adherence\" using multivariate logistic regression analysis", 
                "measure": "Adherence phenotype details", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Short Inflammatory Bowel Disease Questionnaire score at 12 months", 
                "measure": "Quality-of-life score at 12 months", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }
        ], 
        "source": "Beth Israel Deaconess Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Beth Israel Deaconess Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "August 2013"
    }
}